In this interview we discuss the latest on HPV vaccines for cancer prevention and some of the struggles countries face in achieving widespread adoption.
Jack Cuzick, PhD
Advertisement
Articles by Jack Cuzick, PhD
The so-called “carryover” effect of tamoxifen results in the reduction in recurrence continuing well after treatment has stopped. The carryover effect is seen mostly in the first 5 years after treatment cessation, and recent evidence suggests that after that time, it is largely over.
Advertisement
Latest Updated Articles
- Duration of Aromatase Inhibitor Treatment in Breast Cancer: The Role of the ‘Carryover Effect’
Published: December 15th 2013 | Updated:
HPV Vaccines Continue to Improve, But More Uptake RequiredPublished: September 24th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
3
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
